-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, researchers conducted a randomized controlled study to compare the efficacy of anthractic post-prostatectomy assisted radiotherapy or early remedial radiotherapy in patients with local or local advanced prostate cancer.
In adult patients with medium to high risk, limited or localized advanced prostate cancer, assisted radiotherapy or early remedial radiotherapy is performed immediately after a cure-all prostatectomy to detect progression events in patients, including biochemic progression (prostate-specific antigens. PSA≥0.4ng/mL, rising after completion of any postoperative radiotherapy), clinical or radiological progression, other treatment, death from prostate cancer, or randomization of PSA levels above 2.0ng/ml.
end of the study was event-free survival.
3 queues, a total of 2,153 patients completed the study, with an average follow-up time ranged from 60 months to 78 months, with a maximum follow-up time of 132 months.
1,075 patients received assisted radiotherapy and 1,078 patients received early remedial radiotherapy.
the baselines of patients, with an average age of 64-65 years, and the majority of patients (1671 cases (77.6 per cent)) had a Gleason score of 7.
all trials were assessed as having a low risk of bias.
study found that there was no significant improvement in event-free survival (HR 0.95) and a 1 percentage point increase in five-year event-free survival (89% vs88%) compared to early rescue radiotherapy, with overall results consistent between trials.
study, for patients with local or local advanced prostate cancer, receiving complementary radiotherapy after cured surgery could not significantly improve the survival rate of patients without events.
.